The Economics of Prevention AHIA conference Sydney, 9 ... · ACE-Prevention was a 5 year NHMRC...

Post on 06-Jul-2020

0 views 0 download

Transcript of The Economics of Prevention AHIA conference Sydney, 9 ... · ACE-Prevention was a 5 year NHMRC...

The Economics of Prevention AHIA conference

Sydney, 9 November 2010 Prof Theo Vos

Centre for Burden of Disease and Cost-Effectiveness School of Population Health

University of Queensland

For ACE-Prevention Research Team

Overview of the Session

1. Introduction to ACE-Prevention study 2. Results

a) Individual interventions b) Intervention pathways c) Big picture ~ key messages; costs; cost savings;

health gains from recommended packages

2

3

Brief History ACE-Prevention was a 5 year NHMRC Health

Services Research Grant (2005-2009) Across 2 sites (UQ and Deakin) Followed on from earlier ACE studies funded

by both government & competitive grants Largest study of its kind in the world 150 interventions assessed

4

Total population Indigenous Topic Prevention Treatment Prevention Treatment Alcohol 9 2 Tobacco 8 Physical activity 6 Nutrition 26 Body mass 9 Blood pressure/cholesterol 12 5 Bone mineral density 3 Illicit drugs 2 1 Cancer 9 1 Diabetes 7 7 Renal disease 2 2 4 2 Mental disorders 11 10 Cardiovascular disease 1 5 Other 18 6 3 Total 123 27 19 2

Topic areas and interventions

5

Quick overview of economic methods Clear criteria for selection of interventions Standardised evaluation methods to minimise

methodological confounding Evaluation conducted as integral part of exercise

(not collation from literature) ‘Evidence’-based approach with extensive

uncertainty & sensitivity testing Careful thought given to government policy

objectives and concept of ‘benefit’

6

Economic protocol

Perspective Health Sector (focus on government; key societal effects flagged)

Comparator Current practice + no interventions (‘null’) for analyses of intervention mix

Target pop Cohort of patients with conditions/risk factor of interest, Aust. population 2003

Time horizon Track costs & benefits 100 yrs or death Discounting 3% Costs Best available unit costs (documented); Real costs $AUD 2003

7

C/E analysis protocol (Pamphlet C)

Outcomes Cost per DALY saved + 2nd stage filters Uncertainty analysis 95% uncertainty intervals using

probabilistic analysis Sensitivity analysis Test scenarios around key design

features

Reporting ICER point estimates & ranges; league tables cost-effectiveness planes; topic area expansion path; packages of interventions; 2nd stage filters & implications

8

From policy to measurement of benefit

Two-stage approach adopted in ACE First, a measure of health gain in relation to resources

consumed ($ cost per DALY) Picks up element of cost, efficacy/effectiveness and

efficiency objectives

Second, explicitly provide for broader considerations not in this C/E ratio Which we call our ‘2nd stage filters’ (equity; acceptability;

feasibility; size of the problem) Plus confidence in evidence base

Results

9

League table

10

11

DALYs, costs & cost-effectiveness ratios for alcohol interventions

DALYs Intervention

cost Cost offsets Net cost ICER averted $M $M $M $/DALY Taxation increase 30% 100,000 0.6 -530 -530 Dominant Volumetric taxation 11,000 0.6 -57 -56 Dominant Advertising bans 7,800 20 -31 -12 Dominant Minimum drinking age 21 150 0.6 -0.8 -0.2 Dominant Licensing controls 2,700 20 -11 9 3,300 Brief intervention 160 2.3 -1.2 1.1 6,800 Brief intervention + telemarketing 340 6.1 -2.6 3.5 10,000 Random breath testing 2,300 71 -17 54 24,000 Drink drive mass media 1,500 39 -11 28 14,000 Residential treatment & naltrexone 480 59 4.4 55 120,000 Residential treatment 190 37 -1.7 35 150,000

Cobiac L, Vos T, Doran C, Wallace A (2009).Cost-effectiveness of interventions to prevent alcohol-related disease and injury in Australia. Addiction, 104:1646-55

12

Results: cost-effectiveness plane

$50,000/DALY threshold

Volumetric

13

Summary ~ Triage Categories

Dominant interventions Excellent < $10,000/DALY Very Good $10,000 - $50,000/DALY Good >$50,000/DALY Not C/E

Key to results

Health impact (lifetime)

Small

0–10,000

Medium

10,000–100,000

Large

>100,000

DALYs

Intervention cost (annual)

Small <10

Medium 10–100

Large >100

$million

++

++

+

+++

+++

+

14

Dominant interventions Excellent value-for-money Gain health and save costs Need very good reason to reject

Topic area Intervention

Lifetime health impact

Annual intervention

cost Alcohol Volumetric tax ++ +

Tax increase 30% +++ + Advertising bans + + Minimum legal drinking age to 21 + +

Tobacco Tax increase 30% +++ + Physical activity Pedometers ++ ++

Mass media ++ ++ Fruit & veg Community fruit & veg promotion + ++ Salt Voluntary salt limits + +

Mandatory salt limits +++ + Body mass 10% tax on unhealthy food +++ + BP&Chol Community Heart Health Program ++ +

Polypill $200 >5% CVD risk +++ +++

Presenter
Presentation Notes
Health Priority areas include Arthritis and musculoskeletal conditions, asthma, cancer control, cardiovascular health, diabetes, injury prevention and control, mental health (depression), obesity, and risk factors (smoking, phys inact, poor diet and nutrition, bmi, high blood pressure and cholesterol) Break each group into two for visibility and meaning to the audience. Using green for good buys and brown for not so good buys

Topic area Intervention

Lifetime health impact

Annual intervention

cost Osteoporosis Screen women 70+ & alendronate ++ ++

Hepatitis B HBV vaccine + immunoglobulin to infants born to carrier or high risk mothers

+ +

Selective HBV vaccination of infants with mothers from highly endemic countries

+ +

Kidney disease Proteinuria screen & ACE-inhibitor for diabetics

++ +

Mental disorders Problem solving post-suicide attempt

+ +

Treatment for individuals at ultra-high risk for psychosis

+ +

Oral health Fluoridation drinking water non-remote areas

+ +

17

Interventions

< $10,000/DALY Very good buys

Topic area Intervention

Lifetime health impact

Annual intervention

cost Alcohol Brief alcohol intervention GP ±

telemarketing and support + +

Licensing controls + + Tobacco Cessation aid: varenicline ++ +++

Cessation aid: bupropion ++ +++ Cessation aid: NRT ++ ++

Physical activity GP prescription + +++

Internet intervention + ++ Fruit & veg Information mail-out, multiple re-

tailored + +

Body mass Gastric banding +++ +++

Topic area Intervention

Lifetime health impact

Annual intervention

cost BP & chol Low dose diuretics >5% CVD risk +++ +++

Polypill $200 to over 55s +++ +++ Calcium channel blockers >10% CVD risk ++ ++ ACE-inhibitors >15% CVD risk + ++

Mental disorders, drugs, suicide

Screen & bibliotherapy minor depression adults

+ ++

Screening and psychologist to prevent childhood/adolescent depression

+ ++

Screening and bibliotherapy to prevent childhood/adolescent depression

+ +

Responsible media reporting on suicide + +

Parenting intervention for prevention of childhood anxiety disorders

+ +

Other Universal infant HBV vaccination + ++

20

Interventions

$10,000 - $50,000/DALY Good buys

Topic area Intervention

Lifetime health impact

Annual intervention

cost Alcohol Drink drive mass media + ++

Roadside breath testing + ++

Physical activity TravelSmart + +++ GP referral + +++

Nutrition Multiple tailored mailed fruit & vegetable promotion

+ +

Obesity Diet & exercise for overweight + +++

Low-fat diet for overweight + ++

BP & Chol Dietary counselling >5% CVD risk by dietitian

++ ++

Phytosterol >5% CVD risk ++ +++ Statins >5% CVD risk +++ +++ Statins + Ezitimibe >5% CVD risk +++ +++ Beta blockers >5% CVD risk ++ +++ CCBs >5% CVD risk +++ +++ ACE inhibitors >5% CVD risk +++ +++

Topic area Intervention

Lifetime health impact

Annual intervention

cost Cancer Pap screen (current practice) + ++

HPV DNA test screening 3-yearly from 18 + +

HPV vaccination + Pap screen + ++

SunSmart +++ +++

Pre-diabetes Screen + dietary advice + ++ Screen + exercise physiologist ++ ++

Screen + dietary advice & exercise physiologist

++ ++

Screen + metformin ++ ++

Screen + acarbose ++ ++

Kidney disease

Proteinuria screen & ACE-inhibitor for non-diabetics >25 yrs

++ ++

Mental disorders

Screening & group CBT pre-depression + ++

Screening & CBT post-partum depression + +

23

Interventions

>$50,000/DALY Not cost-effective

Other reasons to select?

Topic area Interventions Comment Diet F&V interventions targeting

individuals and at workplace Poor effectiveness

Dietary advice on salt Poor effectiveness Weight watchers Poor maintenance of weight loss Multi-component diet/physical

activity/weight intervention Poor effectiveness

Orlistat, sibutramine Too expensive Osteoporosis Raloxifene Too expensive Mental health / drugs / suicide

School based drug intervention Poor effectiveness

Gun buy- back scheme Poor evidence; high cost

Pre-diabetes Orlistat and rosiglitazone Too expensive

Vision loss Ranibizumab for macula degeneration Too expensive

Shingles Varicella vaccination at age 50 Too expensive/low frequency

25

Insufficient evidence of effectiveness: Dental check-ups Screen vision loss general population Emergency cards for people who attempted suicide Aspirin Front of pack traffic light nutrition labelling Roadside drug testing

More harm than good: PSA testing for prostate cancer

26

‘Benchmark’ interventions

Treatment or infectious disease control

Selected results

Topic area Intervention Lifetime health impact

Annual intervention cost

Dominant Net cost savers HIV Needle exchange program +++ ++

Very cost-effective <$10,000/DALY CVD Rehabilitation after myocardial infarction

+ ++

HIV Circumcision all Men having Sex with Men + ++

Osteoarthritis Hip replacement for osteoarthritis +++ +++ Knee replacement for osteoarthritis +++ +++

Good buys $10,000 - $50,000/DALY Breast cancer Trastuzumab for early breast cancer, 9

week course + ++

CVD Early stenting for myocardial infarction + +++ Angioplasty coated stents in diabetics + ++

Cost-ineffective >$50,000/DALY Alcohol Residential treatment +/- naltrexone + ++ Renal disease Dialysis & transplant ++ +++ CVD Bypass and stents vs medical treatment + +++ HIV Early antiretrovirals ++ ++

Results for 123 prevention measures:

23 net cost saving 20 very cost-effective <$10,000 per healthy life year (DALY) 31 cost-effective $10-50,000 per DALY 38 not cost-effective 2 more harm than good; 2 for which better alternatives 4 insufficient evidence of effectiveness

28

Presenter
Presentation Notes

Very cost-effective and large health impact: Tax alcohol, tobacco and ‘unhealthy food’ Regulation of salt content in bread, cereals and margarine Treating blood pressure and cholesterol …. but doing this

more efficiently than we currently do • using cheaper drugs • better targeting who needs to be treated

Gastric banding for the very obese (but expensive!)

29

Very cost-effective and moderate health impact: Pedometers & mass media for physical activity

Smoking cessation drugs

Screen elderly women for osteoporosis & alendronate

Screen diabetics for chronic kidney disease

30

Very cost-effective & more modest health impact: Fluoride drinking water

Hepatitis B vaccination

A range of 7 measures to prevent mental disorders or suicide

31

Other cost-effective measures: Increased SunSmart effort

HPV vaccination and Pap smear testing cervix cancer

Screen for pre-diabetes + drug or lifestyle intervention

Screen for chronic kidney disease + drug

Diet and exercise for overweight people (but limited

impact on weight loss)

32

Intervention pathways: ‘Ideal mix’

33

34

Alcohol

-$600

-$500

-$400

-$300

-$200

-$100

$0

$100

- 20 40 60 80 100 120 140

Net

lifet

ime

cost

s (m

illio

ns A

US$

200

3) Lifetime DALYs averted (thousands)

Ad bans

RBT

Drink drive mass media

Res. treat. + naltrexone

Licensing controls

Min. legal drinking age to 21 yrs Brief intervention

30% tax

Current practice

Volumetric tax

Physical inactivity

35

-$1,000

-$800

-$600

-$400

-$200

$00 10 20 30 40 50 60 70

Net l

ifetim

e co

st (m

illio

nsAU

S$20

03)

Lifetime DALYs averted (thousands)

Pedometers

GP referralMass media

Internet

GP prescription

TravelSmart

Pre-diabetes screening + lifestyle intervention/ drugs

0

200

400

600

800

1000

1200

0 5000 10000 15000 20000 25000 30000

Tota

l Cos

t ($

mill

ion)

Health Benefits (DALYs)

Diet & ExerciseMetformin$50,000/DALY

36

Blood pressure & cholesterol lowering

37

Phytosterol + Statin+Ezetimibe

≥5%

CCB + ACEi ≥5% + Phytosterol ≥10%

Diuretic+ Dietitian+ Phytosterol ≥5%

Diuretic+ CCB + Dietitian ≥10%

Diuretic+ CCB + Dietitian

≥15%

Diuretic ≥10% CHHP

Diuretic ≥15%

Current practice

- 5,000

-

5,000

10,000

15,000

20,000

25,000

- 100 200 300 400 500 600

Net

Life

time

Cost

s (m

illio

n AU

S$ 2

003)

Lifetime DALYs averted ('000)

38

Blood pressure & cholesterol lowering

CHHP Polypill ≥ 15%

Polypill ≥ 10%

Polypill ≥ 5%

Dietitian ≥ 5%

Phytosterol ≥ 5%

Diuretic + CCB + ACEi ≥5%

Statin+Ezetimibe ≥5%

Current practice

- 5,000

5,000

10,000

15,000

20,000

25,000

100 200 300 400 500 600

Net

Life

time

Cost

s (m

illio

n AU

S$ 2

003)

Lifetime DALYs averted ('000)

39

Blood pressure & cholesterol lowering

Diuretic ≥15% Diuretic 10-14%CCB ≥15%

CCB 10-14%ACEi ≥15%

ACEi 10-14%

Statin ≥15%

Statin 10-14%

ACEi10-14%

ACEi≥15%CCB10-14%

CCB≥15%

Diuretic10-14%Diuretic≥15%StatinNZ10-14%StatinNZ≥15%-$0.5

$0.0

$0.5

$1.0

$1.5

$2.0

$2.5

$3.0

0 20 40 60 80 100 120 140

Net

life

time

cost

s (2

008A

$)B

illio

ns

Lifetime DALYs averted or QALYs gainedThousands

$50,000/DALY or QALY

Cost per year for 40 mg generic simvastatin: Australia: $400 New Zealand: <$20

40

-4,000

-3,000

-2,000

-1,000

00 50 100 150 200 250 300

Net

life

time

cost

s (m

illio

n A

US

$) Lifetime DALYs averted (thousands)

Tax

Lapband

Diet & exercise

Weight loss

41

Dialysis & transplant (current practice)

DM ( 50-79)

Dialysis only

- 200

0

200

400

600

800

5,000 10,000 15,000 20,000

Net

LIfe

time

Cost

(mill

ion

AU$

2003

)

Lifetime DALYs averted

Screening and early treatment

DM ( 40-49)

DM ( 25-39)

Non-DM ( 50-79)

Non-DM ( 40-49)

Non-DM ( 25-39)

Chronic Kidney disease

Blue print for governments: good investments in prevention that are

affordable opportunities for large health improvement potential to reduce wasteful spending

Governments will need strong arguments to ignore the compelling evidence

42

43

Reminder of key results 1. Taxation/regulation interventions tend to be very cost-

effective (from health sector perspective) and have large health impact

2. Great potential to improve efficiency in CVD prevention thru blood pressure and cholesterol lowering and accelerate CVD decline

3. Untapped potential to address pre-diabetes, chronic kidney disease

Presenter
Presentation Notes
I would organise these messages from very positive through to negative

44

Reminder of key results 4. Emerging evidence for a substantial role in prevention

of mental disorders 5. Targeted interventions with drug treatments in CVD

prevention, pre-diabetes, chronic kidney disease, osteoporosis good credentials

6. Targeted interventions aiming to change behaviour tend not to be cost-effective and if so, have modest impact on population health

45

Dissemination of results Written documents:

Intervention briefing papers (standard format) Project report Journal articles 26 brief 4-8 page pamphlets on various aspects of project and

results by topic area

Presentations: Road shows; Conferences; Workshops

Website http://www.uq.edu.au/bodce-ace-prevention